Movement Alert｜BIOCYTOGEN-B Rises 5.43% in Regular Trading, Strategic ADC Collaboration with Whitehawk Therapeutics Boosts Sentiment

Market Focus08-04

On August 4, BIOCYTOGEN-B rose 5.43% in regular trading, trading at HKD 55.5/share, with turnover of HKD 6.3965 million.

The movement was primarily driven by a recently announced global strategic collaboration with Whitehawk Therapeutics. Under the agreement, BIOCYTOGEN will provide up to five fully human bispecific antibodies developed through its proprietary RenLite platform, while Whitehawk will evaluate these antibodies using its ADC linker-payload technology. Whitehawk has the option to advance any resulting BsADC candidates into its pipeline. BIOCYTOGEN will receive upfront payments and potential milestone payments.

Market confidence was further supported by continued institutional accumulation. Fuguo Fund recently increased its stake to 8.23% after purchasing 556,500 shares at approximately HKD 51.81 per share, while E Fund also added to its position. The combination of a high-profile BD collaboration validating the company's platform value and persistent institutional buying has underpinned the stock's upward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133954612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133954612","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 5.43% in Regular Trading, Strategic ADC Collaboration with Whitehawk Therapeutics Boosts Sentiment","media":"Market Focus","content":"<p><p>On August 4, BIOCYTOGEN-B rose 5.43% in regular trading, trading at HKD 55.5/share, with turnover of HKD 6.3965 million.</p><p>The movement was primarily driven by a recently announced global strategic collaboration with Whitehawk Therapeutics. Under the agreement, BIOCYTOGEN will provide up to five fully human bispecific antibodies developed through its proprietary RenLite platform, while Whitehawk will evaluate these antibodies using its ADC linker-payload technology. Whitehawk has the option to advance any resulting BsADC candidates into its pipeline. BIOCYTOGEN will receive upfront payments and potential milestone payments.</p><p>Market confidence was further supported by continued institutional accumulation. Fuguo Fund recently increased its stake to 8.23% after purchasing 556,500 shares at approximately HKD 51.81 per share, while E Fund also added to its position. The combination of a high-profile BD collaboration validating the company's platform value and persistent institutional buying has underpinned the stock's upward momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 5.43% in Regular Trading, Strategic ADC Collaboration with Whitehawk Therapeutics Boosts Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 5.43% in Regular Trading, Strategic ADC Collaboration with Whitehawk Therapeutics Boosts Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, BIOCYTOGEN-B rose 5.43% in regular trading, trading at HKD 55.5/share, with turnover of HKD 6.3965 million.</p><p>The movement was primarily driven by a recently announced global strategic collaboration with Whitehawk Therapeutics. Under the agreement, BIOCYTOGEN will provide up to five fully human bispecific antibodies developed through its proprietary RenLite platform, while Whitehawk will evaluate these antibodies using its ADC linker-payload technology. Whitehawk has the option to advance any resulting BsADC candidates into its pipeline. BIOCYTOGEN will receive upfront payments and potential milestone payments.</p><p>Market confidence was further supported by continued institutional accumulation. Fuguo Fund recently increased its stake to 8.23% after purchasing 556,500 shares at approximately HKD 51.81 per share, while E Fund also added to its position. The combination of a high-profile BD collaboration validating the company's platform value and persistent institutional buying has underpinned the stock's upward momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1133954612","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133954612","pubTimestamp":1785807581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, BIOCYTOGEN-B rose 5.43% in regular trading, trading at HKD 55.5/share, with turnover of HKD 6.3965 million.The movement was primarily driven by a recently announced global strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势警报|BIOCYTOGEN-B 常规交易上涨 5.43%，ADC 与 Whitehawk Therapeutics 的战略合作提振情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 4, BIOCYTOGEN-B rose 5.43% in regular trading, trading at HKD 55.5/share, with turnover of HKD 6.3965 million.The movement was primarily driven by a recently announced global strategic collaboration with Whitehawk Therapeutics. Under the agreement, BIOCYTOGEN will provide up to five fully human bispecific antibodies developed through its proprietary RenLite platform, while Whitehawk will evaluate these antibodies using its ADC linker-payload technology. Whitehawk has the option to advance any resulting BsADC candidates into its pipeline. BIOCYTOGEN will receive upfront payments and potential milestone payments.Market confidence was further supported by continued institutional accumulation. Fuguo Fund recently increased its stake to 8.23% after purchasing 556,500 shares at approximately HKD 51.81 per share, while E Fund also added to its position. The combination of a high-profile BD collaboration validating the company's platform value and persistent institutional buying has underpinned the stock's upward momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133954612","isCrawlerRequest":true}